Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Assets (2016 - 2025)

Ultragenyx Pharmaceutical has reported Assets over the past 11 years, most recently at $1.5 billion for Q4 2025.

  • Quarterly Assets rose 1.93% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 1.93% year-over-year, with the annual reading at $1.5 billion for FY2025, 1.93% up from the prior year.
  • Assets was $1.5 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • Over five years, Assets peaked at $1.6 billion in Q3 2022 and troughed at $1.2 billion in Q3 2025.
  • The 5-year median for Assets is $1.5 billion (2021), against an average of $1.4 billion.
  • Year-over-year, Assets grew 29.57% in 2021 and then dropped 23.5% in 2023.
  • A 5-year view of Assets shows it stood at $1.5 billion in 2021, then rose by 1.51% to $1.5 billion in 2022, then fell by 3.52% to $1.5 billion in 2023, then rose by 0.8% to $1.5 billion in 2024, then rose by 1.93% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Assets are $1.5 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025).